Skip to main
ACAD

ACAD Stock Forecast & Price Target

ACAD Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 47%
Buy 35%
Hold 18%
Sell 0%
Strong Sell 0%

Bulls say

ACADIA Pharmaceuticals is a biopharmaceutical company with a promising pipeline, particularly in the areas of neurological and rare diseases. The success of pimavanserin and remlifanserin in treating psychosis associated with Parkinson's disease and Alzheimer's disease, respectively, as well as the potential approval of trofinetide for Rett syndrome, show potential for revenue growth. However, the company's stock is high risk due to potential drawbacks and competition in the market. Overall, ACADIA has the potential for long-term success, but investors should proceed with caution.

Bears say

ACADIA Pharmaceuticals is currently facing several challenges, such as underwhelming data from its pimavanserin drug in multiple indications, the need for further development and investment in a next-generation drug called remlifanserin, and the risk of competition and market pressure. Additionally, there is uncertainty surrounding the success of its ongoing clinical trials for Alzheimer's and Lewy Body Dementia psychosis. These factors, combined with the potential risks of safety concerns and regulatory hurdles, contribute to the financial analyst's negative outlook on the company's stock.

ACAD has been analyzed by 17 analysts, with a consensus rating of Buy. 47% of analysts recommend a Strong Buy, 35% recommend Buy, 18% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Acadia Pharmaceuticals Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Acadia Pharmaceuticals Inc. (ACAD) Forecast

Analysts have given ACAD a Buy based on their latest research and market trends.

According to 17 analysts, ACAD has a Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $33.41, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $33.41, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Acadia Pharmaceuticals Inc. (ACAD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.